Bristol-Myers Squibb raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sales above consensus. Click here to find out why BMY is a Buy.

By 2026, many exam rooms will have an AI listener that will take notes on the entire conversation and provide structured data ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the ...

Artificial intelligence has quickly become a fixture in healthcare conversations, particularly around clinical documentation, workforce efficiency ...

As we look ahead to 2026, the operational demands on 340B programs are increasing across every dimension. Between the implementation of the 340B ...

Introduction This article outlines the research protocol for a multicentre, randomised, controlled study designed to evaluate the therapeutic effect of a modified olfactory training (MOT) based on ...